Depatuxizumab mafodotin

Depatuxizumab mafodotin
Monoclonal antibody
Type Whole antibody
Source Chimeric/humanized hybrid (mouse/human)
Target EGFR
Clinical data
ATC code none
CAS Number 1585973-65-4
ChemSpider none
Chemical and physical data
Formula C6624H10228N1728O2052S42
Molar mass 148.3 kDa

Depatuxizumab mafodotin (INN) is a chimeric and humanized monoclonal antibody designed for the treatment of cancer.[1][2]

This drug was developed by AbbVie.


  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
  2. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).

This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.